Fig. 1From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trialWaterfall graphs of percentage change in the total sum of target lesion diameters from baseline to postbaseline nadir (RECIST v1.1)Back to article page